Clinical Review on the Management of Metastatic Renal Cell Carcinoma

Renal cell carcinomas vary considerably in their tumor biology and disease course, which is reflected in the range of treatment paradigms in localized and metastatic renal cell carcinoma (mRCC). Active surveillance remains an important component of all renal cell carcinoma management. In mRCC, the rapid evolution from cytokine-based therapy to targeted therapy to immunotherapy with checkpoint blockade has revolutionized the field and drastically altered treatment outcomes. More recently, combination therapies have become a standard of care for most patients with mRCC. In this review, we highlight recent critical data that led to changes in treatment paradigms and provide a practical framework for the management of patients with mRCC.

Automated summary

Renal cell carcinomas show significant variations in tumor biology and disease progression, resulting in diverse treatment paradigms. Combination therapies have become the standard of care for most patients with metastatic renal cell carcinoma. This review highlights recent crucial data that have led to changes in treatment approaches and provides a practical framework for managing patients with mRCC.